Sharekhan

Eris Lifesciences Ltd

Mon 1/12/2025,9:59:53 NSE: ERIS

₹ 1585.30 -10.10 (-0.63%)
BUY NOW Buy Eris Lifesciences Ltd Stock

Open Free Demat and Trading account in 15 minutes

Home Stock Eris Lifesciences Ltd

Mon 1/12/2025,10:12:0

Eris Lifesciences Ltd

Mon 1/12/2025,9:59:53 | NSE : ERIS

₹ 1585.30-10.10 (-0.63%)

Data is delayed. Analysis is best done in real-time! Open a FREE Sharekhan Demat A/c in 15 mins* and continue your analysis with real-time data.

Market Data

Essential tool: analyze, trade, manage, decide.

Open

₹ 1586.00

Previous Close

₹ 1595.40

Volume

7785

Mkt Cap ( Rs. Cr)

₹21594.46

High

₹ 1603.80

Low

₹ 1580.70

52 Week High

₹ 1910.00

52 Week Low

₹ 1097.20

Book Value Per Share

₹ 203.46

Dividend Yield

0.46

Face Value

₹ 1.00

What’s Your Call?

Collective community sentiment on Eris Lifesciences Ltd

Your Vote -

Buy

28.30%

Hold

20.75%

Sell

50.94%

28.30%

53 users have voted

Market Depth

How many stocks are available to buy or sell and at what prices.

Buy Order Quantity

60%

Sell Order Quantity

40%

Bid Price

Qty

1591.70

27

1591.00

6

1591.00

4

1591.00

6

1591.00

1

Bid Total

12472

Bid Price

Qty

1592.80

3

1593.00

3

1593.00

34

1593.00

1

1593.00

3

Bid Total

8152

Option Chain

Analyzes market sentiment, predicts Eris Lifesciences Ltd' movement.

NO_RECORD_FOUND

News

Media spotlight triggers stock stock attention, sentiment.

  • Eris Lifesciences - Copy of Newspaper Publication

    26 Nov 2025, 4:01PM Eris Lifesciences Limited has informed the Exchange about Copy of Newspaper Publication

  • Eris Lifesciences to acquire remaining 30% stake in Swiss Parenterals

    25 Nov 2025, 2:38PM Eris Lifesciences on Tuesday announced that its board has approved the acquisition of the remaining 30% stake in its subsidiary Swiss Parenterals. <p

  • Eris Lifesciences - Shareholders meeting

    24 Nov 2025, 9:06PM Eris Lifesciences Limited has informed the Exchange regarding Notice of Postal Ballot

  • Eris Lifesciences - Shareholder Meeting / Postal Ballot-Notice of Postal Ballot

    24 Nov 2025, 9:06PM as attached

  • Eris Lifesciences - Announcement under Regulation 30 (LODR)-Acquisition

    24 Nov 2025, 6:40PM Acquisition of remaining 30% shares of Swiss Parenterals Limited

  • Eris Lifesciences - Issue of Securities

    24 Nov 2025, 6:34PM Eris Lifesciences Limited has informed the Exchange about issue of Securities

  • Eris Lifesciences - Announcement under Regulation 30 (LODR)-Issue of Securities

    24 Nov 2025, 6:34PM As attached

  • Eris Lifesciences - Outcome of Board Meeting

    24 Nov 2025, 6:25PM Eris Lifesciences Limited has informed the Exchange regarding Board meeting held on November 24, 2025.

  • Eris Lifesciences - Board Meeting Outcome for Meeting Dated November 24, 2025

    24 Nov 2025, 6:07PM As attached

  • Eris Lifesciences - Outcome of Board Meeting

    24 Nov 2025, 6:06PM Eris Lifesciences Limited has informed the Exchange regarding Outcome of Board Meeting held on November 24, 2025.

  • Eris Lifesciences - Board Meeting Intimation for Issuance Of Equity Shares Of The Company By Way Of A Preferential Issue

    19 Nov 2025, 2:43PM Eris Lifesciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 24/11/2025 ,inter alia, to consider an

  • Eris Lifesciences - ESOP/ESOS/ESPS

    17 Nov 2025, 6:46PM Eris Lifesciences Limited has informed the Exchange regarding Allotment of 3337 Shares.

  • Eris Lifesciences - Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS

    17 Nov 2025, 6:39PM Allotment of 3,337 Equity shares pursuant to ESOP-2021 Scheme

  • Eris Lifesciences - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    14 Nov 2025, 5:32PM Investor meet intimation

  • Eris Lifesciences - Analysts/Institutional Investor Meet/Con. Call Updates

    14 Nov 2025, 5:32PM Eris Lifesciences Limited has informed the Exchange about Schedule of meet

  • Eris Lifesciences - Analysts/Institutional Investor Meet/Con. Call Updates

    14 Nov 2025, 5:25PM Eris Lifesciences Limited has informed the Exchange about Transcript

  • Eris Lifesciences - Announcement under Regulation 30 (LODR)-Earnings Call Transcript

    14 Nov 2025, 5:21PM Earnings Call Transcript

  • Eris Lifesciences - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome

    12 Nov 2025, 8:03PM as attached

  • Eris Lifesciences - Analysts/Institutional Investor Meet/Con. Call Updates

    12 Nov 2025, 8:00PM Eris Lifesciences Limited has informed the Exchange about Link of Recording

  • Eris Lifesciences Q2 net profit zooms 432.28% at Rs 149.57 cr

    12 Nov 2025, 6:43PM The company reported standalone net profit of Rs 149.57 crore for the quarter ended September 30, 2025 as compared to Rs 28.10 crore in the same perio

  • Eris Lifesciences - Outcome of Board Meeting

    12 Nov 2025, 6:32PM Eris Lifesciences Limited has submitted to the Exchange, the financial results for the period ended September 30, 2025.

  • Eris Lifesciences - Outcome of Board Meeting

    12 Nov 2025, 1:47PM Outcome of Board Meeting

  • Eris Lifesciences - Investor Presentation

    12 Nov 2025, 1:41PM Eris Lifesciences Limited has informed the Exchange about Investor Presentation

  • Eris Lifesciences - Outcome of Board Meeting

    12 Nov 2025, 1:36PM Eris Lifesciences Limited has informed the Exchange regarding Board meeting held on November 12, 2025.

  • Eris Lifesciences - Announcement under Regulation 30 (LODR)-Investor Presentation

    12 Nov 2025, 1:46PM as attached

  • Eris Lifesciences - Unaudited Financial Results For The Quarter And Half Year Ended September 30, 2025

    12 Nov 2025, 1:44PM as attached

  • Eris Lifesciences - Board Meeting Outcome for Unaudited Financial Results For The Quarter And Half Year Ended September 30, 2

    12 Nov 2025, 1:37PM as attached

  • Eris Lifesciences - Analysts/Institutional Investor Meet/Con. Call Updates

    6 Nov 2025, 7:06PM Eris Lifesciences Limited has informed the Exchange about Schedule of meet

  • Eris Lifesciences - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    6 Nov 2025, 7:05PM As attached

  • Eris Lifesciences - Board Meeting Intimation for Consideration And Approval Of Unaudited Standalone And Consolidated Financia

    6 Nov 2025, 6:58PM Eris Lifesciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/11/2025 ,inter alia, to consider an

  • Eris Lifesciences has submitted to BSE the Shareholding Pattern for the Period Ended September 30, 2025

    17 Oct 2025, 6:50PM As of September 2025, 54.85% is owned by Indian Promoters and 45.15% by Public. <p align=justify> Institutional holds 26.57% (Insurance Companies 1.20

  • Eris Lifesciences - Certificate under SEBI (Depositories and Participants) Regulations, 2018

    13 Oct 2025, 2:56PM Eris Lifesciences Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018

  • Eris Lifesciences - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

    13 Oct 2025, 2:53PM Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

  • Eris Lifesciences - Trading Window

    26 Sep 2025, 12:12PM Eris Lifesciences Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations

  • Eris Lifesciences - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    11 Sep 2025, 2:37PM Investor meet intimation

  • Eris Lifesciences - Analysts/Institutional Investor Meet/Con. Call Updates

    11 Sep 2025, 2:37PM Eris Lifesciences Limited has informed the Exchange about Schedule of meet

  • Eris Lifesciences - Analysts/Institutional Investor Meet/Con. Call Updates

    2 Sep 2025, 3:03PM Eris Lifesciences Limited has informed the Exchange about Schedule of meet

  • Eris Lifesciences - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    2 Sep 2025, 3:09PM Investor meet intimation

  • Eris Lifesciences Ltd

    25 Nov 2025 , 10:32AM Eris Lifescience : The company is set to buy the remaining 30% stake in its subsidiary, Swiss Parenterals, from Naishadh Shah for Rs 423.3 crore. In exchange, the company will issue 23.06 lakh shares on a preferential basis to Naishadh Shah. The proposed transaction is expected to complete tentatively before March 31, 2026. Currently, Eris Lifesciences holds a 70% stake in Swiss Parenterals.

  • Eris Lifesciences receives ANVISA approval for Sterile Injectable Facility

    26 Aug 2025 , 12:05PM Eris Life sciences receives Brazil health regulator nod for sterile injectable facility in Ahmedabad

  • Eris Lifesciences receives ANVISA approval at its Ahmedabad campus

    25 Aug 2025 , 12:38PM ANVISA is Brazil's National Health regulatory agency

  • Eris Lifesciences to acquire 19% equity stake in Swiss Parenterals

    15 Mar 2024 , 11:26AM Eris Lifesciences to acquire 19% equity stake in Swiss Parenterals for Rs. 237.50 crore

  • Eris Lifesciences buys nine dermatology brands from Dr.Reddy's

    16 Mar 2023 , 2:34PM Eris Lifesciences acquires nine dermatology brands from Dr Reddy's for Rs. 275 cr

  • Eris Lifesciences

    18 Jan 2023 , 11:02AM Eris Lifesciences Ltd. has decided to deepen its presence in the anti-fungal and anti-psoriasis segments, by acquiring a portfolio of dermatology brands from Glenmark Pharma for Rs. 340 Cr. The deal is to purchase 9 brands such as Onabet, Halobate, Sorvate, and Demelan for India and Nepal.

  • Eris Lifesciences

    8 Jun 2022 , 12:22PM As per media reports, German drug maker Boehringer Ingelheim has obtained ad-interim injunctions against four domestic pharmaceutical companies - Eris Lifesciences, Emcure Pharma, Optimus Pharma and MSN Laboratories, that launched generic versions of Boehringer Ingelheim’s patent-protected drug Linagliptin, which is marketed under the brand name, Trajenta. The injunction restraints the Pharmaceutical companies from selling, advertising, importing or exporting drug in any form in India unit the next hearing date. Boehringer Ingelheim holds a valid patent for Linagliptin in India until August 2023. Sentimentally negative read thru for Eris Lifesciences

  • Eris Lifesciences

    4 May 2022 , 9:45AM The company has acquired 100% stake in OAKNET HEALTHCARE PRIVATE Ltd, a pharmaceutical company operating in the Indian markets with a presence in the Dermatology, Gynecology, Pain Management, Nutritional, Cardiology & Diabetes therapy areas. The acquisition is done for a cash consideration of Rs 650 cr and the company has tied up for a debt amounting to Rs 350 crs for the acquisition. Oaknet has reported revenues of Rs 185.75 crore for FY21, Rs 191.5 cr for FY20 and Rs 163.49 for FY19. The acquisition is expected to benefit Eris as it would strengthen its presence in the Dermatology space by expanding product portfolio and increasing market penetration. However on the FY21 sales the deal translates in to a valuation of 3.4x (Ev/Sales) which looks to be on the higher side, though we would await further updates on the possible synergies from the acquisition for Eris

  • Eris Lifesciences

    6 Dec 2021 , 12:06PM The company has entered in to a Joint Venture (JV) with MJ biopharma and would focus on the insulins segment. As per the terms of the agreement Eris would have a 70% stake in the JV while MJ Biopharma would hold the balance 30% stake. The JV company shall be engaged in the marketing and distribution of the recombinant human insulin and insulin analogs and the first product to be commercialized would be a Recombinant Human Insulin while going ahead more bio-pharmaceutical products are expected to be launched by the JV. The JV marks the foray of Eris into the field of Biopharmaceuticals with a focus on the insulins segment, which has a strong potential growth prospects. We currently, do not have any recommendation on Eris Lifesciences.

  • Eris Lifesciences

    4 Dec 2019 , 2:40PM Acquired trademark ‘Zomelis’ from Novartis for Indian pharma market for $13 million. Positive read thru

  • Eris Lifesciences board nod share buyback

    3 Jul 2019 , 1:27PM Board approves share buyback for up to 17.39 lakh shares at Rs 575/Share

  • Eris Lifesciences board to consider buyback of shares

    25 Jun 2019 , 10:41AM Board to consider Buyback of equity shares

  • Eris Life, HEG up in weak market

    19 Mar 2018 , 11:25AM Shares of Eris Lifesciences and HEG surges after Vanguard Group purchased bulk shares of these companies through open market transactions on Friday (March 16, 2018).

  • Eris gains after credit suisse initiates coverage

    28 Nov 2017 , 12:23PM Eris Life rises over 5% to Rs684, after Credit Suisse initiates coverage on the stock with an 'outperform'

  • Eris Lifesciences enters into agreement with Strides

    20 Nov 2017 , 12:04PM Eris Lifesciences enters into a definitive agreement for sale of Strides’ India branded generics business to Eris for an aggregate cash consideration of Rs500 crs

  • Eris Lifesciences acquires Strides Shasun’s domestic bizz

    20 Nov 2017 , 8:56AM Neutral read through for Strides Shasun in view of the acquisition.

  • Eris up as RBI allows hike in foreign investment limit

    23 Aug 2017 , 2:40PM Eris rises over 3% to Rs607.05, after central bank allows hike in investment limit by foreign portfolio investors from 24% to 49% of its paid up capital
Load More
Show Less

Key fundamentals

Evaluate the intrinsic value of Eris Lifesciences Ltd stock 

Name March-25 March-24 March-23 March-22 March-21
Assets 4727.85 5053.471 2538.755 1918.556 1575.467
Liabilities 4727.85 5053.471 2538.755 1918.556 1575.467
Equity 13.62 13.603 13.599 13.593 13.578
Gross Profit 486.55 453.814 505.114 483.995 417.314
Net Profit 77.39 299.712 398.008 417.192 350.605
Cash From Operating Activities 701.86 336.289 322.328 369.412 395.409
NPM(%) 4.55 20.15 29.9 34.31 31.61
Revenue 1697.75 1486.706 1330.725 1215.73 1108.834
Expenses 1211.2 1032.892 825.611 731.735 691.52
ROE(%) 2.79 10.81 14.36 15.05 12.65

Shareholding Pattern

Corporate Action

XD-Date Dividend-Amount Dividend-% Dividend Yield(%GE) Price on that day
13 Feb 2025 7.35 735 0.46 1453.75
11 Aug 2022 7.35 735 0.46 704.05
05 Aug 2021 6.01 601 0.46 755.6
13 Aug 2020 5.5 550 0.46 510.95
19 Mar 2020 2.87 287 0.46 431.9

Peers

Other companies within the same industry or sector that are comparable to Eris Lifesciences Ltd

Company Price Price (% change) pe(x) EV/EBITDA(x) ROE(%) ROCE(%)
Albert David Ltd 795.10 0.28 0.00 919.57 301.39 0.63
Lotus Eye Hospital and Institute Ltd 105.10 -0.52 328.44 3350.80 3.55 0.00
Vaishali Pharma Ltd 8.80 0.11 0.00 21020.71 3.13 0.00
Astec Lifesciences Ltd 820.00 -2.14 0.00 3159.89 -604.77 0.00

Company Info

The Company was incorporated as "Eris Lifescience Private Limited" on January 25, 2007, as a private limited company under the Companies Act 1956, at Ahmedabad, with a certificate of incorporation granted by the Registrar of Companies, Gujarat, Dadra and Nagar Haveli. Pursuant to a resolution of the Shareholders dated February 5, 2007, the name of the Company was changed to "Eris Lifesciences Private Limited" and a fresh certificate of incorporation was issued by the Registrar of Companies, Gujarat, Dadra and Nagar Haveli on February 9, 2007. Further, pursuant to a conversion of the Company to a public limited company, and as approved by the Shareholders through a resolution dated January 31, 2017, the name was changed to "Eris Lifesciences Limited" and the RoC issued a fresh certificate of incorporation on February 2, 2017. Major events and milestones The table below sets forth some of the major events in the history of the Company. 2007 -Incorporation of the Company -Launched "Eris" division focused on cardiology and diabetes segment 2008 -Launched "Nikkos" division focused on gastroenterology and orthopedics segment 2009 -Launched "Adura" division focused on cardiology and diabetes segment 2011 -Launched "Montana" division focused on gynecology and pediatrics segment 2012 -Launched "Inspira" division focused on cardiology segment 2013 -Awarded 'Competitive Strategy Leadership' award by Frost & Sullivan -Awarded 'Emerging Companies Excellence' award for scalability of business model and managing operational efficiencies by Business Today and Yes Bank 2014 -Launched "Victus" division focused on anti-diabetes segment -Set up Assam Facility by the Company 2015 -Launched "Eris 2" division focused on pain management segment 2016 -Acquired 40 registered and unregistered trademarks from Amay Pharmaceuticals Private Limited (now, Aprica Pharmaceuticals Private Limited) -Acquired 100.00% of the outstanding equity shares of Aprica Healthcare Private Limited -Acquired 75.48% of the outstanding equity shares of Kinedex Healthcare Private Limited 2017 -Acquired the trademarks `UNION', `REUNION' and `BON UNION' 2022 -Eris Enters Dermatology Therapy Through The Acquisition Of Oaknet Healthcare For Inr 6,500 Mn. 2023 -""Eris announces the acquisition of Nephrology and Dermatology Branded Formulations business units of Biocon Biologics in India"". 2024 -The Company informed the Exchange about the acquisition of 30% stake in Levim Lifetech Private Limited. -The Company Informed acquisition of 100% stake in Eris Pharmaceuticals Private Limited.

The Company was incorporated as "Eris Lifescience Private Limited" on January 25, 2007, as a private limited company under the Companies Act 1956, at Ahmedabad, with a certificate of incorporation granted by the Registrar of Companies, Gujarat, Dadra and Nagar Haveli. Pursuant to a resolution of the Shareholders dated February 5, 2007, the name of the Company was changed to "Eris Lifesciences Private Limited" and a fresh certificate of incorporation was issued by the Registrar of Companies, Gujarat, Dadra and Nagar Haveli on February 9, 2007. Further, pursuant to a conversion of the Company to a public limited company, and as approved by the Shareholders through a resolution dated January 31, 2017, the name was changed to "Eris Lifesciences Limited" and the RoC issued a fresh certificate of incorporation on February 2, 2017. Major events and milestones The table below sets forth some of the major events in the history of the Company. 2007 -Incorporation of the Company -Launched "Eris" division focused on cardiology and diabetes segment 2008 -Launched "Nikkos" division focused on gastroenterology and orthopedics segment 2009 -Launched "Adura" division focused on cardiology and diabetes segment 2011 -Launched "Montana" division focused on gynecology and pediatrics segment 2012 -Launched "Inspira" division focused on cardiology segment 2013 -Awarded 'Competitive Strategy Leadership' award by Frost & Sullivan -Awarded 'Emerging Companies Excellence' award for scalability of business model and managing operational efficiencies by Business Today and Yes Bank 2014 -Launched "Victus" division focused on anti-diabetes segment -Set up Assam Facility by the Company 2015 -Launched "Eris 2" division focused on pain management segment 2016 -Acquired 40 registered and unregistered trademarks from Amay Pharmaceuticals Private Limited (now, Aprica Pharmaceuticals Private Limited) -Acquired 100.00% of the outstanding equity shares of Aprica Healthcare Private Limited -Acquired 75.48% of the outstanding equity shares of Kinedex Healthcare Private Limited 2017 -Acquired the trademarks `UNION', `REUNION' and `BON UNION' 2022 -Eris Enters Dermatology Therapy Through The Acquisition Of Oaknet Healthcare For Inr 6,500 Mn. 2023 -""Eris announces the acquisition of Nephrology and Dermatology Branded Formulations business units of Biocon Biologics in India"". 2024 -The Company informed the Exchange about the acquisition of 30% stake in Levim Lifetech Private Limited. -The Company Informed acquisition of 100% stake in Eris Pharmaceuticals Private Limited.

Read More

Parent Organisation

Eris Lifesciences Ltd.

Founded

25/01/2007

Managing Director

NSE Symbol

ERISEQ

FAQ

The current price of Eris Lifesciences Ltd is ₹ 1585.30.

The 52-week high for Eris Lifesciences Ltd is ₹ 1603.80 and the 52-week low is ₹ 1580.70.

The market capitalization of Eris Lifesciences Ltd is currently ₹ 21594.46. This value can fluctuate based on stock price movements and changes in the number of shares outstanding.

To buy Eris Lifesciences Ltd shares, you need to have a brokerage account. First, choose a reputable brokerage firm, open an account, and complete the necessary KYC procedures.

To invest in Eris Lifesciences Ltd, you need a brokerage account. After opening an account and completing the KYC process, you can fund your account and use the trading platform to purchase Eris Lifesciences Ltd shares.

The CEO of Eris Lifesciences Ltd is , who has been leading the company with a vision to expand its renewable energy portfolio and drive sustainable growth.

OPEN FREE* DEMAT ACCOUNT